iSpecimen Inc. announced a $5.5 million private placement of Series C Convertible Preferred Stock to ease liquidity concerns. The funding aims to support marketing and working capital needs.
Amount Raised
$5.5 Million
Round Type
Series C
Description
iSpecimen Inc entered into a securities purchase agreement for nearly $5.5 million in gross proceeds through the issuance of preferred shares. The funding will assist with marketing, working capital, and other corporate needs. The transaction is expected to close around December 31. This move follows a significant decline in stock price, helping to alleviate near-term liquidity concerns.
Who else raised in Healthcare and E Commerce around the same time
Companies in the same sectors as iSpecimen that raised within 45 days of this round, from Fundz verified event records.
- CytoDyn raised $19M on January 30, 2026.
- NeOnc Technologies raised $11M on January 29, 2026.
- Enveric Biosciences raised $1.5M on January 28, 2026.
- Ocugen raised $23M (Post-IPO Equity) on January 26, 2026.
- Novabay raised $134M on January 16, 2026.
- Os Therapies raised $3.5M on January 14, 2026.
Who to call at iSpecimen, and when
A new round usually means iSpecimen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day iSpecimen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at iSpecimen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at iSpecimen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment iSpecimen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
iSpecimen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.